数据链接：
官方服务：
资源简介：
Fab Fragment of Anti-human LAG3 antibody (22D2)
应用场景：
创建时间：
2024-10-23
相关数据集
table1_Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?.docx
Background: Combination therapy with immune checkpoint inhibitors (ICIs) has been widely used for clinical treatment in recent years, which has a better survival benefit. However, not all patients can
NIAID Data Ecosystem100
Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CRISPR Screen]. Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CRISPR Screen]
Following nearly five decades with few approved therapies for acute myeloid leukemia (AML), the last three years have brought stellar progress with the U.S. Food and Drug Administration approving a nu
NIAID Data Ecosystem50
BindingDB Entry 50018444: Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.
Small molecule binding data for protein Platelet-derived growth factor receptor alpha/beta, Programmed cell death 1 ligand 1, and Programmed cell death 1 ligand 2, Uniprot P05622, P26618, Q9BQ51, Q9EP
DataCite Commons2024-04-26 更新30
Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation
Several monoclonal antibodies targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway have been used successfully in anticancer immunotherapy. Inherent limitations of
NIAID Data Ecosystem60
IMT-2021-0145 Supplementary Tables
Supplementary Table 1. 1L treatments received by treatment class (N=501) Supplementary Table 2. Reasons for end of follow-up for patients who did not receive 2L treatment Supplementary Table 3. Subgro
Figshare2021-08-04 更新40
